Parabilis Medicines, Inc. (NASDAQ:PBLS) Stock Now Rated “Moderate Buy” by Wall Street Analysts

Posted by Geri Gentry on Oct 20th, 2026

Parabilis Medicines, Inc. (NASDAQ:PBLS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the seven analysts that are covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, four have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price target among analysts that have covered the stock in the last year is $41.67.

Several brokerages recently weighed in on PBLS. Weiss Ratings raised shares of Parabilis Medicines from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday. Guggenheim assumed coverage on shares of Parabilis Medicines in a research note on Monday, July 6th. They issued a “buy” rating and a $40.00 target price for the company. Leerink Partners assumed coverage on shares of Parabilis Medicines in a research report on Monday, July 6th. They issued an “outperform” rating and a $40.00 target price for the company. Zacks Research raised shares of Parabilis Medicines to a “hold” rating in a research report on Tuesday, July 7th. Finally, Lifesci Capital upgraded shares of Parabilis Medicines to a “strong-buy” rating in a research note on Monday, July 6th.

Get Our Latest Research Report on PBLS

Institutional Investors Weigh In On Parabilis Medicines

Several institutional investors and hedge funds have recently modified their holdings of PBLS. ARCH Venture Management LLC bought a new stake in Parabilis Medicines in the second quarter worth $175,517,789. venBio Partners LLC acquired a new position in Parabilis Medicines during the second quarter worth $144,149,497. Alphabet Inc. bought a new position in Parabilis Medicines during the second quarter valued at about $134,647,000. Regeneron Pharmaceuticals Inc. bought a new position in Parabilis Medicines during the second quarter valued at about $114,042,000. Finally, Jupiter Topco LLC bought a new position in Parabilis Medicines during the second quarter valued at about $62,710,000.

Parabilis Medicines Price Performance

PBLS opened at $25.35 on Thursday. Parabilis Medicines has a fifty-two week low of $22.66 and a fifty-two week high of $42.49. The business’s 50-day moving average price is $34.99. The stock has a market cap of $3.13 billion and a P/E ratio of -11.90.

Parabilis Medicines (NASDAQ:PBLS – Get Free Report) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $0.15 million during the quarter. Equities analysts forecast that Parabilis Medicines will post -3.09 earnings per share for the current year.

About Parabilis Medicines

(Get Free Report)

Parabilis Medicines Inc is a clinical-stage biopharmaceutical company built to develop transformative medicines addressing some of the most consequential, yet historically undruggable, protein targets driving human disease. Parabilis Medicines Inc is based in CAMBRIDGE, Mass.